journal
MENU ▼
Read by QxMD icon Read
search

Current Vascular Pharmacology

journal
https://www.readbyqxmd.com/read/28707604/chinese-herbal-medicine-for-hyperlipidaemia-a-review-based-on-data-mining-from-1990-to-2016
#1
Liang Dai, Aiping Lu, Linda L D Zhong, Guang Zheng, Zhaoxiang Bian
BACKGROUND: Many studies have shown that the reduction of low density lipoprotein (LDL-C) levels provides cardiovascular protection; therefore LDL-C is considered to be a core therapeutic target in anti-hyperlipidaemia treatment. However, the LDL-C goal attainment is often not satisfied in China with conventional lipid-lowering agents. Many patients seek help from Chinese Herbal Medicine (CHM). To further understand the current use of CHM in hyperlipidaemia, we conducted a review based on a systematic literature search and data mining...
July 13, 2017: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/28707603/ginseng-for-the-treatment-of-hypertension-a-systematic-review-and-meta-analysis-of-double-blind-randomized-placebo-controlled-trials
#2
Hye Won Lee, Hyun- Ja Lim, Ji Hee Jun, Jiae Choi, Myeong Soo Lee
BACKGROUND: Evidence of ginseng for reducing blood pressure (BP) in hypertensive patients is controversial. This systematic review updated the previous reviews and evidence for it. METHODS: Ten databases were searched from their inception through October 2016, without language restriction. Randomized clinical trials (RCTs) were included if any types of ginseng were tested as the sole treatment or as an adjunct to other treatments for pre-hypertension or hypertension...
July 12, 2017: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/28707602/ginkgo-biloba-extract-in-vascular-protection-molecular-mechanisms-and-clinical-applications
#3
Jinfan Tian, Yue Liu, Keji Chen
Background Leaves of Ginkgo biloba, a "living fossil," have been used as traditional herbal medicine for hundreds of years in China. Currently, its application in vascular protection is gaining much attention. Methods In this manuscript, preclinical studies were reviewed to discuss various mechanisms underlying the vascular protection by Ginkgo biloba extract (GBE). Additionally, we reviewed clinical studies to present the application of GBE in the ischaemic disease. Results GBE, a commonly used as a dietary supplement, has been shown to act as an antioxidant and free-radical scavenger, a membrane stabilizer, an inhibitor of the platelet-activating factor, a vasodilator, and a regulator of metabolism...
July 12, 2017: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/28707601/potential-role-of-natural-compounds-as-anti-angiogenic-agents-in-cancer
#4
Muthu K Shanmugam, Sudha Warrier, Alan Prem Kumar, Gautam Sethi, Frank Arfuso
BACKGROUND: Neovascularization, also known as angiogenesis, is the process of capillary sprouting from pre-existing blood vessels. This physiological process is a hallmark event in normal embryonic development as blood vessels generally supply both oxygen and nutrients to the cells of the body. Any disruption in this process can lead to the development of various chronic diseases, including cancer. In cancer, aberrant angiogenesis plays a prominent role in maintaining sustained tumor growth to malignant phenotypes and promoting metastasis...
July 12, 2017: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/28677510/the-management-of-dyslipidaemia-in-patients-with-type-2-diabetes-mellitus-receiving-lipid-lowering-drugs-a-sub-analysis-of-the-cepheus-findings
#5
Abdullah Shehab, Khalid Al-Rasadi, Mohamed Arafah, Ali T Al-Hinai, Wael Al Mahmeed, Akshaya Srikanth Bhagavathula, Omer Al Tamimi, Shorook Al Herz, Faisal Al Anazi, Khalid Al Nemer, Othman Metwally, Akram Alkhadra, Mohammed Fakhry, Hossam Elghetany, Abdel Razak Medani, Afzal Hussein Yusufali, Obaid Al Jassim, Omar Al Hallaq, Fahad Omar Ahmed S Baslaib, Mahmoud Alawadhi, Haitham Amin, Khamis Al-Hashmi, Abderrahim Oulhaj
BACKGROUND: Dyslipidaemia is a risk factor for macrovascular complications in patients with type 2 diabetes mellitus (T2DM). Our aim was to assess the use of lipid lowering drugs (LLDs) in patients with T2DM and co-existing dyslipidaemia. METHOD: A multicentre, non-interventional survey conducted in 6 Middle Eastern countries (Bahrain, Oman, Qatar, United Arab Emirates, Kingdom of Saudi Arabia and Kuwait). Patients with T2DM (n = 3338) who received LLD treatment for ≥3 months with no dose change for ≥6 weeks were enrolled...
July 5, 2017: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/28677509/therapy-of-cardiac-arrhythmias-in-children-an-emerging-role-of-electroanatomical-mapping-systems
#6
Casale Matteo, Mezzetti Maurizio, Tulino Viviana, Michele Scarano, Busacca Paolo, Dattilo Giuseppe
INTRODUCTION: Cardiac arrhythmias are challenging diseases in childhood. Most of them in pediatric subjects (90.2%) are atrioventricular reentrant tachycardias and atrioventricular nodal reentrant tachycardias. The standard 12-lead ECG is a highly accurate diagnostic tool but an invasive electrophysiological study is often required. The main concern about this kind of procedures is their invasive nature and the need of radiations, so antiarrhythmic agents are currently the first line therapy...
July 5, 2017: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/28669329/effect-of-low-5-mg-vs-high-20-40-mg-rosuvastatin-dose-on-24h-arterial-stiffness-central-haemodynamics-and-non-alcoholic-fatty-liver-disease-in-patients-with-optimally-controlled-arterial-hypertension
#7
Eudoxia Mitsiou, Chrysoula Boutari, Vasilios Kotsis, Eleni Georgianou, Michael Doumas, Asterios Karagiannis, Vasilios G Athyros
OBJECTIVE: Arterial stiffness (AS) and non-alcoholic fatty liver diseases (NAFLD) are 2 related, prevalent, risk predictors of cardiovascular disease (CVD). We assessed the effect of low dose (5 mg/day) vs high dose (20-40 mg/day) rosuvastatin on aortic elasticity and central haemodynamics as well as on NAFLD in patients with arterial hypertension (AH). PATIENTS-METHODS: Forty patients with optimally controlled AH were randomised to 2 rosuvastatin doses and followed for 6 months...
June 30, 2017: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/28676022/patients-with-acute-coronary-syndrome-are-at-high-risk-prior-to-the-event-and-lipid-management-is-underachieved-pre-and-post-hospitalization
#8
C Vlachopoulos, G Andrikopoulos, D Terentes-Printzios, S Tzeis, E K Iliodromitis, D Richter, I Mantas, A Kartalis, V Vasilikos, D Stakos, S Patsilinakos, S Lampropoulos, D Symeonidis, C Kyrpizidis, N Marinakis, N Nikas, J Lekakis, D Tousoulis, P Vardas
BACKGROUND: Current European Guidelines suggest the use of cardiovascular risk categories and also recommend using high-intensity statins for patients with acute coronary syndromes (ACS). OBJECTIVE: We examined the risk of ACS patients prior to the event, as well as the overall use and intensity of statins. METHOD: We enrolled 687 ACS patients (mean age 63 years, 78% males). Low-density lipoprotein cholesterol (LDL-C) levels upon admission were used to assess attainment of LDL-C targets...
June 21, 2017: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/28676027/the-co-existence-of-nash-and-chronic-kidney-disease-boosts-cardiovascular-risk-are-there-any-common-therapeutic-options
#9
Marianna Papademetriou, Vasilios G Athyros, Eleni Geladari, Michael Doumas, Costas Tsioufis, Vasilios Papademetriou
Non-alcoholic fatty liver disease (NAFLD) is becoming the most common chronic liver disease. NAFLD may evolve to non-alcoholic steatohepatitis (NASH), which is causally related to cirrhosis and cardiovascular disease (CVD) mortality. There is no generally accepted effective treatment for NAFLD/NASH. Chronic kidney disease (CKD) is relatively common and might co-exist with NAFLD/NASH, aggravate one another, and increase CVD risk. Common therapies could improve outcome. Potent statins at high doses, such as atorvastatin and rosuvastatin, ameliorate NAFLD/NASH and reduce the mortality rates by half as compared with those on the same statins but without liver disease...
June 20, 2017: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/28676026/a-critical-approach-of-guideline-therapeutic-recommendations-for-nafld
#10
Dragan B Djordjevic, Marija Zdravkovic, Aleksandar Nagorni, Athanasios Manolis, Costas Tsioufis, Dragan Lovic
Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) as progressive form of the disease are associated with cardiovascular risk factors including obesity, dyslipidaemia, hyperglycaemia and hypertension. When NAFLD is associated with cardiovascular disease, mortality of NAFLD patients is increased due to cardiovascular disease. Prevalence of NAFLD and NASH is high, but it seems that epidemic of the disease is under-recognized and under-appreciated. Linking pathophysiological mechanisms are complex and still not well understood...
June 20, 2017: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/28676025/nonalcoholic-fatty-liver-disease-vs-nonalcoholic-steatohepatitis-pathological-and-clinical-implications
#11
Chrysoula Boutari, Petros Lefkos, Vasilios G Athyros, Asterios Karagiannis, Konstantinos Tziomalos
The implications and prognosis of nonalcoholic fatty liver (NAFL) and nonalcoholic steatohepatitis (NASH) are substantially different. The aim of the present review is to describe and compare the pathological and clinical implications of these two conditions. Patients with NASH have a higher risk of progressing to cirrhosis than patients with NAFL but without steatohepatitis, who tend to have a non-progressive disease and only a minority progresses to NASH. Patients with NASH also are at greater risk to develop hepatocellular cancer (HCC) and NASH is the third commonest cause of HCC...
June 20, 2017: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/28676024/nafld-nash-an-under-recognized-epidemic
#12
Joseph Jennings, Charles Faselis, Michael D Yao
First described in 1980, nonalcoholic fatty liver disease (NAFLD) has become more common although the exact incidence and prevalence is unknown. While the exact prevalence varies from region to region, the overall trend shows an increased number of patients with NAFLD. Risk factors for the development of NAFLD includes advanced age, male gender, obesity, and having elements of the metabolic syndrome. There is also an association between the presence of NAFLD and coronary atherosclerosis. Persons of Hispanic descent tend to have higher rates of NAFLD when compared with other populations...
June 20, 2017: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/28676023/vascular-endothelial-growth-factor-inhibitor-therapy-and-cardiovascular-and-renal-damage-in-renal-cell-carcinoma
#13
Silvia Lai, Alessio Molfino, Patrizia Seminara, Flavia Longo, Georgie Innico, Bettina Coppola, Daniela Mastroluca, Alessandro Galani, Mira Dimko, Paola Aceto, Carlo Lai
BACKGROUND: Sunitinib, a tyrosine kinase inhibitor of vascular endothelial growth factor (VEGF), is approved for first and second line treatment of advanced renal cell carcinoma (RCC). Knowledge on the effects of sunitinib on cardiovascular (CV) risk and renal damage is limited. AIM: To evaluate possible renal and CV damage in patients with RCC treated with sunitinib. MATERIALS AND METHODS: Patients with metastatic RCC treated with sunitinib were enrolled...
June 20, 2017: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/28676021/medical-management-and-risk-reduction-of-the-cardiovascular-effects-of-underwater-diving
#14
Thomas F Whayne
Undersea diving is a sport and commercial industry. Knowledge of potential problems began with Caisson disease or "the bends", first identified with compressed air in the construction of tunnels under rivers in the 19th century. Subsequently, there was the commercially used old-fashioned diving helmet attached to a suit, with compressed air pumped down from the surface. Breathhold diving, with no supplementary source of air or other breathing mixture, is also a sport as well as a commercial fishing tool in some parts of the world...
June 20, 2017: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/28676020/current-and-potential-future-pharmacological-approaches-for-non-alcoholic-fatty-liver-disease
#15
Konstantinos Imprialos, Konstantinos Stavropoulos, Sofia Bouloukou, Georgios Kerpiniotis, Asterios Karagiannis, Michael Doumas
BACKGOUND: Non-alcoholic fatty liver disease (NAFLD) affects a large proportion of the general population. The disease ranges from simple steatosis, to non-alcoholic steatohepatitis (NASH), cirrhosis and even hepatocellular carcinoma. Several drugs are used in daily clinical practice to manage the disease. However, data on their efficacy in liver histology are not consistent. AIM: We discuss current treatment options for NAFLD and NASH and preliminary results from novel drugs under investigation...
June 20, 2017: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/28676019/statins-an-under-appreciated-asset-for-the-prevention-and-the-treatment-of-nafld-or-nash-and-the-related-cardiovascular-risk
#16
Vasilios G Athyros, Chrysa Boutari, Konstantinos Stavropoulos, Panagiotis Anagnostis, Konstantinos P Imprialos, Michael Doumas, Asterios Karagiannis
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease (30% of the general population) and up to 40% of cases advance to the more severe form of the disease: non-alcoholic steatohepatitis (NASH), which is causally related to cirrhosis and cardiovascular disease (CVD). There is no generally accepted effective treatment for NAFLD/NASH. The joint guidelines of the European Association for the Study of the Liver (EASL), the European Association for the Study of Diabetes (EASD) and the European Association for the Study of Obesity (EASO) suggest the "off label" use of pioglitazone in patients without type 2 diabetes mellitus (T2DM) and pioglitazone in subjects with T2DM or vitamin E or their combination for the treatment of NASH; however pioglitazone has considerable limitations: weight gain, bone fractures in women, and heart failure...
June 20, 2017: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/28676018/can-serum-uric-acid-lowering-therapy-contribute-to-the-prevention-or-treatment-of-nonalcoholic-fatty-liver-disease
#17
Paschalis Paschos, Vasilios G Athyros, Achilleas Tsimperidis, Anastasia Katsoula, Nikolaos Grammatikos, Olga Giouleme
Nonalcoholic fatty liver disease (NAFLD), the most common chronic liver disease in Western countries with potential progression to nonalcoholic steatohepatitis (NASH) and cirrhosis, is associated with cardiovascular disease (CVD) mortality. Several studies have reported a relationship between uric acid and NAFLD/NASH and it seems that serum uric acid (SUA) is a significant independent factor for the development of NAFLD. Potential mediating mechanisms include insulin resistance, endothelial dysfunction, and activation of inflammasome, especially NLRP3...
June 20, 2017: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/28669328/is-nonalcoholic-fatty-liver-disease-indeed-the-hepatic-manifestation-of-metabolic-syndrome
#18
Niki Katsiki, Pablo Perez-Martinez, Panagiotis Anagnostis, Dimitri P Mikhailidis, Asterios Karagiannis
Metabolic syndrome (MetS) is a cluster of central obesity, dyslipidaemia, insulin resistance and hypertension. MetS frequently co-exists with non-alcoholic fatty liver disease (NAFLD), which is characterized by fat accumulation in the liver in the absence of alcohol abuse, viral hepatitis and other causes of chronic liver diseases. Both MetS and NAFLD are associated with an increased risk for cardiovascular disease and type 2 diabetes mellitus. There are also other associations between MetS and NAFLD. In the present narrative review, we discuss the links between MetS and NAFLD in terms of prevalence, risk factors and treatment (both lifestyle interventions and drug therapy)...
June 20, 2017: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/28637408/lifestyle-modifications-in-non-alcoholic-fatty-liver-disease-and-non-alcoholic-steatohepatitis
#19
Konstantinos Stavropoulos, Konstantinos Imprialos, Andreas Pittaras, Charles Faselis, Puneet Narayan, Peter Kokkinos
Non-alcoholic fatty liver disease (NAFLD) is one of the most common diseases worldwide, affecting more than 30% of general population. High-fat diets, physical inactivity and obesity, all prevalent in the western societies, are strongly associated with the development and progression of NAFLD. Current drug therapies have not consistently shown substantial beneficial effects. Thus, lifestyle modification appears to be the optimal intervention in combating the disease. Accordingly, several studies have concluded that weight loss, via increase in physical activity, and dietary interventions could potential ameliorate biochemical, histological, and structural abnormalities of non-alcoholic fatty liver disease...
June 20, 2017: Current Vascular Pharmacology
https://www.readbyqxmd.com/read/28595561/sexual-dysfunction-cardiovascular-risk-and-effects-of-pharmacotherapy
#20
Konstantinos P Imprialos, Konstantinos Stavropoulos, Michael Doumas, Konstantinos Tziomalos, Asterios Karagiannis, Vasilios G Athyros
Sexual dysfunction affects millions of people with an increasing prevalence, worldwide. The pathophysiology of the disease shares several similarities with cardiovascular disease (CVD), including atherosclerosis, endothelial dysfunction, structural vascular damage and subclinical inflammation. Erectile dysfunction (ED) and female sexual dysfunction are common among patients with CVD and risk factors such as hypertension, diabetes, obesity and metabolic syndrome. Given the common pathogenesis of the diseases, ED is an independent prognostic factor of future ED events...
June 9, 2017: Current Vascular Pharmacology
journal
journal
40308
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"